Chitosan for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Chitosan for Health & Longevity

Created on 09/18/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A charged fibre from shellfish or fungal material that works entirely inside the digestive tract, binding fat and bile. The dependable finding is a small fall in total and harmful cholesterol, with small improvements in blood sugar. Weight effects are minor. It is well tolerated — an inexpensive, modest addition to cholesterol control rather than a weight-loss tool. (Full Review)

Protocol

Standard dose
3 g daily
Usually 1.5 g twice daily or 1 g three times daily; the dose used in most modern trials and the condition of the authorised European cholesterol claim.
Timing relative to food
With the fattiest meals
Immediately before or with the two or three largest fat-containing meals, since the polymer can only bind lipid present in the gut at the same time.
Split rather than single dosing
Divided across meals
Trial regimens are uniformly divided. A single daily dose is not used, because binding capacity is consumed by one meal.
Time to effect
Cholesterol
8–13 weeks
Lipid changes emerge over this window in the trial literature; nothing measurable happens in the first few weeks.
Glucose control
Beyond 13 weeks
Subgroup analyses show glucose benefit only beyond 13 weeks, and only at 1.6–3 g daily.
Liver enzymes
8 weeks
The window over which liver enzymes fell in fatty liver disease at 1.5 g daily.

Benefits

Contraindications
  • Documented crustacean-shellfish allergy, unless a fungal-source product is used
  • Pregnancy and breastfeeding, and anyone under 18 years
  • Anticoagulation with a vitamin K antagonist targeting an INR of 2.0–3.0 or higher, unless INR is formally monitored
  • Established poor nutrient absorption (Crohn's disease, coeliac disease, chronic pancreatitis, Roux-en-Y gastric bypass)
  • Prior bowel obstruction, intestinal narrowing, or gastroparesis
  • Body mass index below 18.5 kg/m², or unintentional weight loss greater than 5% in 6 months
Key Interactions
  • Lipophilic prescription drugs with a narrow safety margin (ciclosporin, digoxin, levothyroxine, tacrolimus)
  • Lipase inhibitors (orlistat)
  • Over-the-counter fat-soluble vitamins (vitamin A, D, E and K preparations, cod liver oil)
  • Over-the-counter mineral supplements (ferrous sulfate, calcium carbonate, zinc gluconate)
  • Bulk-forming and osmotic laxatives (psyllium, methylcellulose, macrogol)
  • Additive lipid-lowering supplements (red yeast rice, plant sterols, psyllium, berberine, soluble β-glucan)
  • Additive weight and glucose supplements (glucomannan, chromium picolinate, Nigella sativa)
  • Other interventions (bariatric surgery, very-low-fat diets, fat-soluble drug implants)

Risk & Side Effects

  • High: Gastrointestinal effects: constipation, flatulence and bloating; fat-soluble vitamin and carotenoid malabsorption
  • Medium: Rise in alkaline phosphatase
    •
  • Low: Enhanced anticoagulant effect of warfarin; allergic reaction in people with crustacean-shellfish allergy
  • Speculative: Reduced gut microbial diversity; mineral binding and reduced calcium, iron and zinc absorption

Monitoring

Marker Target Why
LDL cholesterol Below 100 mg/dL; below 70 mg/dL where cardiovascular risk is high The best-supported chitosan endpoint
Apolipoprotein B (apoB) Below 80 mg/dL; below 60 mg/dL for aggressive risk reduction Counts plaque-forming particles directly, which LDL cholesterol only estimates
Total cholesterol 160–200 mg/dL The endpoint the authorised European claim rests on
HbA1c (glycated haemoglobin) 4.8–5.4% Long-term glucose control, improved in pooled trials
Fasting glucose 75–86 mg/dL The glucose marker with the most consistent chitosan signal
Fasting insulin 2–5 μIU/mL Detects insulin resistance before glucose rises
Alkaline phosphatase 45–80 U/L Rose in the one placebo-controlled trial that measured it
25-hydroxyvitamin D 40–60 ng/mL The fat-soluble vitamin most exposed to a fat binder
Serum retinol and α-tocopherol Retinol 40–70 μg/dL; α-tocopherol 12–20 mg/L Direct test of fat-soluble vitamin depletion
Ferritin 50–100 ng/mL in women; 75–150 ng/mL in men Screens for the mineral binding suggested by animal work
High-sensitivity C-reactive protein Below 0.5 mg/L General inflammation, and needed to interpret ferritin
INR (international normalised ratio) The individual's prescribed target, commonly 2.0–3.0 Chitosan is reported to potentiate warfarin's effect
Body-fat percentage Below 25% in men; below 32% in women Tracks the body-composition endpoint that pooled trials moved slightly
Waist circumference Below 94 cm in men; below 80 cm in women Abdominal fat responds before total weight

Cadence: Baseline before the first dose; lipid panel, glucose markers and alkaline phosphatase at 12 weeks; lipids, glucose markers and liver enzymes every 6 months; fat-soluble vitamins, ferritin and body composition every 12 months. On a vitamin K antagonist, INR 1 week after any change.

Qualitative Assessment

  • Stool form and frequency, scored daily on the Bristol Stool Scale for the first 4 weeks, since constipation is the signal most likely to appear
  • Abdominal bloating, flatulence and fullness after fat-containing meals
  • Appetite and satiety between meals, which the appetite-hormone findings would predict changing
  • Energy levels and exercise tolerance, as a check that nothing is being depleted
  • How clothing fits, as a slower but more honest read on abdominal fat than scale weight
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.